Nomination committee appointed ahead of AGM 2026 in SynAct Pharma AB

Pursuant to the instruction and charter for the Nomination Committee adopted at the AGM held on May 28, 2024, the Nomination Committee shall consist of four members, representing the three largest shareholders as per end of September, together with the chairman of the Board of Directors.

Based on the above, the Nomination Committee for the AGM 2026 has been established to consist of the following persons:

• Mark Gandrup, appointed by Sanos ApS
• Thomas Ringberg
• Niels Ankerstjerne Sloth appointed by TJ Biotech ApS
• Anders Kronborg, Chairman of the Board

In total, the Nomination Committee represents more than 20% of the total number of shares and votes in the company as of September 30, 2025.

The task of the Nomination Committee is to prepare and present proposals to the AGM regarding the Chairman of the AGM, the election of the Chairman and other members of the Board of Directors, the remuneration of the Board of Directors divided between the Chairman and the other members, any remuneration for Committee work and the election and remuneration of the auditor. Finally, the Nomination Committee will propose principles for the appointment of the Nomination Committee (if the Nomination Committee considers that the
current principles and instructions should be updated).

Shareholders are welcome to submit their proposals and views to the Nomination Committee to SynAct Pharma AB, Att: Nomination Committee, c/o SynAct Pharma, Medicon Village, Scheelevägen 2, 223 63 Lund, or by e-mail to valberedning@synactpharma.com.

To ensure that proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but no later than January 31, 2026.

The Nomination Committee's proposals will be announced in the notice for the AGM 2025 and on SynAct’s web site.